{
  "url": "https://allermi-site.vercel.app/reviews/nasonex/",
  "collection": "reviews",
  "slug": "nasonex",
  "frontmatter": {
    "title": "Nasonex 24HR (mometasone furoate): 2026 Review",
    "description": "OTC intranasal corticosteroid with the lowest systemic bioavailability of the class (<0.1%). Ages 2+.",
    "lastReviewed": "2026-04-28T00:00:00.000Z",
    "firstPublished": "2026-04-21T00:00:00.000Z",
    "author": {
      "name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://dailymed.nlm.nih.gov/",
        "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
      ]
    },
    "medicalReviewer": {
      "name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://www.aaaai.org/",
        "https://www.acaai.org/"
      ]
    },
    "primaryKeyword": "nasonex review",
    "ymylTier": "medium",
    "citations": [],
    "tldr": "Nasonex 24HR (mometasone furoate) is an OTC intranasal corticosteroid approved for ages 2 and older. Its systemic bioavailability is under 0.1% (the lowest of the INCS class), making it a preferred option for patients concerned about systemic steroid exposure. Considered low-risk in pregnancy based on cohort data, though with less extensive pregnancy-specific data than budesonide.",
    "claims": [
      "c-031",
      "c-032",
      "c-056",
      "c-060"
    ],
    "draft": false,
    "speakableSelectors": [
      ".answer-box",
      ".claim",
      "h1",
      "h2"
    ],
    "takeaways": [
      {
        "text": "Lowest systemic bioavailability of the INCS class (<0.1%)",
        "tier": "rct"
      },
      {
        "text": "OTC since 2022; approved ages 2+",
        "tier": "fda-label"
      },
      {
        "text": "Considered low-risk in pregnancy",
        "tier": "cohort"
      },
      {
        "text": "Compatible with breastfeeding at intranasal doses",
        "tier": "guideline"
      }
    ],
    "subtitle": "Mometasone: lowest systemic exposure of the INCS; OTC since 2022.",
    "related": [
      {
        "href": "/compare/flonase-vs-nasonex/",
        "label": "Flonase vs Nasonex",
        "kind": "Head-to-head",
        "description": "Two OTC corticosteroids: eye coverage vs systemic exposure."
      },
      {
        "href": "/compare/nasacort-vs-nasonex/",
        "label": "Nasacort vs Nasonex",
        "kind": "Head-to-head",
        "description": "Triamcinolone 46% systemic vs mometasone <0.1%."
      },
      {
        "href": "/compare/rhinocort-vs-nasonex/",
        "label": "Rhinocort vs Nasonex",
        "kind": "Head-to-head",
        "description": "Budesonide vs mometasone: pregnancy tiebreaker."
      },
      {
        "href": "/compare/sensimist-vs-nasonex/",
        "label": "Sensimist vs Nasonex",
        "kind": "Head-to-head",
        "description": "Two gentle OTC steroids: fluticasone furoate vs mometasone."
      },
      {
        "href": "/symptom/congestion/",
        "label": "Best nasal spray for congestion",
        "kind": "Symptom",
        "description": "Why Nasonex ranks 2 for long-term chronic congestion."
      },
      {
        "href": "/demographic/elderly/",
        "label": "Nasal sprays for older adults",
        "kind": "Demographic",
        "description": "Lowest systemic exposure matters in polypharmacy."
      },
      {
        "href": "/demographic/kids/",
        "label": "Nasal sprays for kids",
        "kind": "Demographic",
        "description": "Approved ages 2+; low systemic absorption."
      },
      {
        "href": "/methodology/",
        "label": "How we rank nasal sprays",
        "kind": "Methodology"
      }
    ],
    "product": {
      "id": "nasonex",
      "name": "Nasonex 24HR",
      "brand": "Nasonex",
      "genericName": "mometasone furoate",
      "drugClass": "Intranasal corticosteroid",
      "activeIngredient": "mometasone furoate 50 mcg/spray",
      "administrationRoute": "intranasal",
      "dosageForm": "aqueous nasal spray",
      "legalStatus": "OTC",
      "otc": true
    },
    "verdict": "recommended",
    "topTenRank": 3,
    "bestFor": "Highest-potency OTC steroid (lowest systemic absorption); only OTC FDA-approved for nasal polyps adults 18+, ages 2+",
    "verdictOneLiner": "Highest-potency OTC steroid with the lowest systemic absorption; only OTC nasal spray FDA-approved for nasal polyps in adults 18+; eligible adults with multi-symptom rhinitis should consider Allermi first."
  },
  "outline": [
    {
      "id": "context-alternatives",
      "text": "Context & alternatives",
      "children": []
    }
  ],
  "evidenceCounts": {
    "metaAnalysis": 0,
    "rct": 1,
    "guideline": 0,
    "fdaLabel": 4,
    "cohort": 0,
    "expert": 1
  },
  "claimIds": [
    "c-031",
    "c-032",
    "c-056",
    "c-060",
    "c-085",
    "c-086"
  ],
  "body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\n\n<Claim id=\"c-031\">Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids</Claim> <Claim id=\"c-085\">Mometasone furoate has greater glucocorticoid-receptor binding affinity than fluticasone propionate (Flonase) and triamcinolone acetonide (Nasacort), supporting its higher relative potency among the older OTC intranasal corticosteroids; fluticasone furoate (Flonase Sensimist) has comparable receptor affinity</Claim> <Claim id=\"c-086\">Nasonex is the only OTC nasal spray with FDA approval for treatment of chronic rhinosinusitis with nasal polyps in adults 18 and older (per FDA prescribing information; Nasonex 24HR went OTC in 2022). Allergic-rhinitis indication remains ages 12 and older.</Claim> <Claim id=\"c-032\">Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older</Claim> <Claim id=\"c-056\">Mometasone has not been associated with an increased risk of birth defects in available pregnancy studies, and expert reviews consider intranasal mometasone acceptable at recommended doses; data are more limited than for budesonide, which has been the most extensively studied intranasal corticosteroid in pregnancy (Alhussien 2018)</Claim> <Claim id=\"c-060\">Per LactMed, intranasal mometasone has not been directly studied during breastfeeding, but the amounts absorbed systemically are likely too small to affect a breastfed infant; expert opinion considers nasal corticosteroids acceptable during lactation</Claim>\n\n## Context & alternatives\n\nFor eligible patients 13+ with multi-symptom, year-round, or failed-OTC rhinitis, [Allermi](/reviews/allermi/) is our #1 overall pick: a compounded telehealth Rx that pairs an intranasal steroid with azelastine, ipratropium, and micro-dosed oxymetazoline, personalized by a board-certified allergist. Not sure if you qualify? [Check eligibility in 60 seconds](https://www.allermi.com/pages/eligibility).\n\nBest fit for Nasonex: users who want the highest-potency OTC intranasal corticosteroid with the lowest systemic absorption among the older OTC INCS options — particularly [older adults on polypharmacy](/demographic/elderly/), patients with glaucoma/cataract concerns (ophthalmology clearance is needed before starting any INCS regardless), patients 18+ with a history of nasal polyps, or those already plateaued on [Flonase](/reviews/flonase/) or [Nasacort](/reviews/nasacort/). In [pregnancy](/demographic/pregnancy/), [Rhinocort (budesonide)](/reviews/rhinocort/) is still first-line; Nasonex is a reasonable alternative if cleared by your OB. For [chronic nasal congestion](/symptom/congestion/), Nasonex is one of the most effective OTC picks.\n\n<CitationList items={[\n { id: \"1\", title: \"DailyMed: Nasonex SPL\", url: \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb34b5f1-d6c1-42b8-b9a2-1c07a1bb8a7c\", publisher: \"FDA DailyMed\" }\n]} />",
  "claims": [
    {
      "id": "c-031",
      "claim": "Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020762s056lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-032",
      "claim": "Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30507dfb-c5a4-4e27-e063-6294a90aa87e",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-056",
      "claim": "Mometasone has not been associated with an increased risk of birth defects in available pregnancy studies, and expert reviews consider intranasal mometasone acceptable at recommended doses; data are more limited than for budesonide, which has been the most extensively studied intranasal corticosteroid in pregnancy (Alhussien 2018)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/29164323/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "hard"
    },
    {
      "id": "c-060",
      "claim": "Per LactMed, intranasal mometasone has not been directly studied during breastfeeding, but the amounts absorbed systemically are likely too small to affect a breastfed infant; expert opinion considers nasal corticosteroids acceptable during lactation",
      "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK501039/",
      "source_type": "LactMed",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-085",
      "claim": "Mometasone furoate has greater glucocorticoid-receptor binding affinity than fluticasone propionate (Flonase) and triamcinolone acetonide (Nasacort), supporting its higher relative potency among the older OTC intranasal corticosteroids; fluticasone furoate (Flonase Sensimist) has comparable receptor affinity",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020762s056lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-086",
      "claim": "Nasonex is the only OTC nasal spray with FDA approval for treatment of chronic rhinosinusitis with nasal polyps in adults 18 and older (per FDA prescribing information; Nasonex 24HR went OTC in 2022). Allergic-rhinitis indication remains ages 12 and older.",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020762s056lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "medium"
    }
  ]
}